1. Home
  2. ZBRA vs GH Comparison

ZBRA vs GH Comparison

Compare ZBRA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zebra Technologies Corporation

ZBRA

Zebra Technologies Corporation

HOLD

Current Price

$201.70

Market Cap

12.9B

Sector

Industrials

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$85.78

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZBRA
GH
Founded
1969
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
13.3B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
ZBRA
GH
Price
$201.70
$85.78
Analyst Decision
Buy
Strong Buy
Analyst Count
8
20
Target Price
$339.75
$117.80
AVG Volume (30 Days)
724.8K
1.7M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.74
EPS
8.18
N/A
Revenue
$5,396,000,000.00
$982,021,000.00
Revenue This Year
$13.42
$33.40
Revenue Next Year
$5.54
$28.55
P/E Ratio
$24.78
N/A
Revenue Growth
8.33
32.88
52 Week Low
$201.64
$36.36
52 Week High
$352.66
$120.74

Technical Indicators

Market Signals
Indicator
ZBRA
GH
Relative Strength Index (RSI) 30.08 30.55
Support Level N/A $54.39
Resistance Level $271.13 $103.16
Average True Range (ATR) 8.07 4.09
MACD -2.96 -0.81
Stochastic Oscillator 0.29 19.47

Price Performance

Historical Comparison
ZBRA
GH

About ZBRA Zebra Technologies Corporation

Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: